LATEST NEWS

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation

(November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata... Continue Reading

Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment

(November 28, 2018)

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker... Continue Reading

FDA Approves Venclexta Combination for AML in Adults

(November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid... Continue Reading

Patients with rare, incurable digestive tract cancers respond to new drug combination

(November 19, 2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some... Continue Reading

REFERENCE AND TOOLS
LOCATIONS
Jackson Oncology Associates, PLLC
The Hederman Cancer Center
1227 North State Street, Suite 101
Jackson, MS 39202
TEL: (601)355-2485
FAX: (601)353-1463
Click Here for Map

Jackson Oncology Associates, PLLC
2368 Grove Street
Vicksburg, MS 39180
TEL: (601)638-3447
FAX: (601)630-9227
Click Here for Map
Jackson Oncology Associates, PLLC
St. Dominic Cancer Center
2969 Curran Drive North, Suite 200
TEL: (601)974-5600
FAX: (601)974-5699
Click Here for Map



Jackson Oncology Associates, PLLC
King's Daughters Hospital
427 Highway 51 North
Brookhaven, MS 39601
TEL: (601)355-2495
Click Here for Map